STAGE 4 PANCREATIC
CANCER TREATMENT
Stage 4 pancreatic cancer deserves honesty. It is one of the most treatment-resistant cancer types. Molecular testing identifies the minority with specific targeted options. Clinical trials are appropriate for almost every patient.
Stage 4 Pancreatic Cancer Treatment Options
| Treatment | Patient Group | Key Data |
|---|---|---|
| FOLFIRINOX (or mFOLFIRINOX) | ECOG 0-1; good performance status | PRODIGE 4/ACCORD 11: improved OS vs gemcitabine alone. Most effective regimen available. |
| Gemcitabine plus nab-paclitaxel | ECOG 1-2; less fit for FOLFIRINOX | Improved OS vs gemcitabine alone with better tolerability. Preferred for moderate performance status. |
| Olaparib maintenance | BRCA1/2-mutated; no progression after 16 weeks platinum | POLO trial: significantly improved PFS vs placebo. First targeted option specifically approved for PDAC. |
| Pembrolizumab | MSI-H/dMMR PDAC (~1-2%) | Tumour-agnostic approval applies. Test MSI at diagnosis. |
| Clinical trials | All patients | Given limited standard options, trial participation is actively appropriate at any line -- not just last resort. |
Frequently Asked Questions
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Questions About Stage 4 Pancreatic Cancer Treatment?
CancerFax connects stage 4 pancreatic cancer patients with specialist oncologists and clinical trial programmes matched to their molecular profile.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified oncologist before making treatment decisions.